Skip to main content

Table 3 Evolution of lipid parameters and blood pressure after 2 years of follow-up in the NEPTUNO study [30]

From: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report

 

CNIC-Polypill

(n = 1614)

Monocomponents

(n = 1614)

Equipotent

(n = 1614)

Other Therapies

(n = 1614)

Difference between baseline and study end

Lipid profile, mg/dL, mean (SD)

 Total cholesterol,

–54.9 (43.2)*

–42.8 (45.2)* †

–31.7 (43.3)* †

–31.7 (42.4)* †

 LDL cholesterol,

–19.6 (38.2)*

–12.9 (42.2)* ‡

–12.3 (39.7)* †

–9.1 (41.2)* †

 HDL cholesterol,

6.5 (10.2)*

4.6 (10.5)* †

3.8 (11.0)*‡

2.8 (11.0)*

 Triglycerides

–67.5 (98.7)*

–59.9 (80.3)* ‡

–56.1 (77.1)* †

–54.4 (79.5)* †

Blood pressure, mm Hg, mean (SD)

 SBP

–14.1 (24.8)*

–11.7 (23.9)* ‡

–10.4 (24.3)* †

–10.4 (23.6)* †

 DBP

–4.5 (13.3)*

–2.5 (12.0)* †

–2.1 (12.4)* †

–1.2 (12.7)* †

Patients with CVRF control at the study end, %

 LDL-c < 70 mg/dL

15.4*

12.5* †

12.8* †

11.6 †

 Triglycerides < 150 mg/dL

50.9*

43.4* †

42.3* †

40.7* †

 SBP < 130/80 mm Hg

44.1*

37.9*, **

34.6‡

32.4‡

  1. Source: Adapted from Gonzalez-Juanatey. Int J Cardiol. 2022;361:116–123 [30]. Reproduced with permission
  2. DBP Diastolic blood pressure, HDL High-density lipoprotein, LDL Low-density lipoprotein, SBP Systolic blood pressure, SD Standard deviation
  3. *p < 0.001 vs baseline
  4. p < 0.001; ‡p < 0.01; and **p < 0.05 change vs reference cohort: CNIC-Polypill